OBJECTIVE: To study the relationships between 1-2 year changes in well-known physician-rated measurements (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT)) and the long-term (≥ 5 years) outcome in patient-reported outcome (PRO) measures (Multiple Sclerosis Impact Scale (MSIS-29), Multiple Sclerosis Walking Scale (MSWS-12)) that reflect the patient-perceived impact of disease, in progressive MS. METHODS: We selected all progressive patients having at least two complete visits within 1-2 years, from a larger cohort of prospectively-followed MS patients. These were invited for another visit, at least 5 years later, consisting of another series of similar examinations, plus 2 PRO scales: the MSIS-29 and MSWS-12. We explored associations between early changes in physician-rated measurements and the long-term outcome as per the PRO measures. RESULTS: In this study,134 patients fulfilled the selection criteria. We found that early change in T25FW was the only physician-rated change that was significantly related to long-term physical impact experienced by the patient, as was assessed by MSIS-29 (Kruskal-Wallis test: χ(2)=7.8, p=0.020). Early T25FW change, and to a lesser degree early 9HPT change, were significantly related to the reported long-term walking limitations, as assessed by MSWS-12 (Kruskal-Wallis test: χ(2)=13.8 and p=0.001 for T25FW, χ(2)=6.5 and p=0.038 for 9HPT). None of the early physician-rated changes were related to the long-term psychological impact experienced by the patient. CONCLUSION: Early changes on physician-rated scales do have long-term impact in terms of potentially predictive value of outcomes for groups of patients in progressive MS, regarding walking limitations and more global physical impact. Surprisingly, early change in T25FW, rather than early change in EDSS, was significantly associated with longer-term patient-reported disease impact. Our study data support the value of using early physician-rated examinations in clinical trials in progressive MS.
OBJECTIVE: To study the relationships between 1-2 year changes in well-known physician-rated measurements (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test (9HPT)) and the long-term (≥ 5 years) outcome in patient-reported outcome (PRO) measures (Multiple Sclerosis Impact Scale (MSIS-29), Multiple Sclerosis Walking Scale (MSWS-12)) that reflect the patient-perceived impact of disease, in progressive MS. METHODS: We selected all progressive patients having at least two complete visits within 1-2 years, from a larger cohort of prospectively-followed MS patients. These were invited for another visit, at least 5 years later, consisting of another series of similar examinations, plus 2 PRO scales: the MSIS-29 and MSWS-12. We explored associations between early changes in physician-rated measurements and the long-term outcome as per the PRO measures. RESULTS: In this study,134 patients fulfilled the selection criteria. We found that early change in T25FW was the only physician-rated change that was significantly related to long-term physical impact experienced by the patient, as was assessed by MSIS-29 (Kruskal-Wallis test: χ(2)=7.8, p=0.020). Early T25FW change, and to a lesser degree early 9HPT change, were significantly related to the reported long-term walking limitations, as assessed by MSWS-12 (Kruskal-Wallis test: χ(2)=13.8 and p=0.001 for T25FW, χ(2)=6.5 and p=0.038 for 9HPT). None of the early physician-rated changes were related to the long-term psychological impact experienced by the patient. CONCLUSION: Early changes on physician-rated scales do have long-term impact in terms of potentially predictive value of outcomes for groups of patients in progressive MS, regarding walking limitations and more global physical impact. Surprisingly, early change in T25FW, rather than early change in EDSS, was significantly associated with longer-term patient-reported disease impact. Our study data support the value of using early physician-rated examinations in clinical trials in progressive MS.
Authors: Ruggero Capra; Mario Alberto Battaglia; Antonio Gaudioso; Laura Lopes; Damiano Paolicelli; Marco Paoloni; Carlo Pozzilli; Valter Santilli; Claudio Solaro; Maria Trojano Journal: J Neurol Date: 2014-01-22 Impact factor: 4.849
Authors: Jan-Patrick Stellmann; Anneke Neuhaus; Christian Lederer; Martin Daumer; Christoph Heesen Journal: PLoS One Date: 2014-03-20 Impact factor: 3.240
Authors: N Voloshyna; E Havrdová; M Hutchinson; T Nehrych; X You; S Belachew; C Hotermans; D Paes Journal: Eur J Neurol Date: 2014-12-15 Impact factor: 6.089
Authors: Ludwig Kappos; Helmut Butzkueven; Heinz Wiendl; Timothy Spelman; Fabio Pellegrini; Yi Chen; Qunming Dong; Harold Koendgen; Shibeshih Belachew; Maria Trojano Journal: Mult Scler Date: 2017-05-30 Impact factor: 6.312
Authors: Nicholas G LaRocca; Lynn D Hudson; Richard Rudick; Dagmar Amtmann; Laura Balcer; Ralph Benedict; Robert Bermel; Ih Chang; Nancy D Chiaravalloti; Peter Chin; Jeffrey A Cohen; Gary R Cutter; Mat D Davis; John DeLuca; Peter Feys; Gordon Francis; Myla D Goldman; Emily Hartley; Raj Kapoor; Fred Lublin; Gary Lundstrom; Paul M Matthews; Nancy Mayo; Richard Meibach; Deborah M Miller; Robert W Motl; Ellen M Mowry; Rob Naismith; Jon Neville; Jennifer Panagoulias; Michael Panzara; Glenn Phillips; Ann Robbins; Matthew F Sidovar; Kathryn E Smith; Bjorn Sperling; Bernard Mj Uitdehaag; Jerry Weaver Journal: Mult Scler Date: 2017-08-11 Impact factor: 6.312
Authors: Jules D Miehm; John Buonaccorsi; Jongil Lim; Sumire Sato; Caitlin Rajala; Julianna Averill; Farnaz Khalighinejad; Carolina Ionete; Stephanie L Jones; Jane A Kent; Richard Ea van Emmerik Journal: Mult Scler J Exp Transl Clin Date: 2020-08-31